Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing

Patrizia Leone, Simona Berardi, Maria Antonia Frassanito, Roberto Ria, Valli De Re, Sebastiano Cicco, Stefano Battaglia, Paolo Ditonno, Franco Dammacco, Angelo Vacca, Vito Racanelli

Blood (2015) 126 (12): 1443–1451.

https://doi.org/10.1182/blood-2015-01-623975

Published: 2015

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

Blood (2013) 122 (21): 3211.

https://doi.org/10.1182/blood.V122.21.3211.3211

Published: 2013

Journal Articles

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Antonella Caivano, Francesco La Rocca, Alessandra Favole, PhD, Sonia Carturan, PhD, Enrico Bracco, PhD, Oreste Villani, Giuseppe Pietrantuono, Ilaria Laurenzana, Luciana De Luca, MD, Annalisa Morano, Vittorio Simeon, Stefania Trino, Simona Berardi, Antonio Basile, Angelo Vacca, Pellegrino Musto, Daniela Cilloni, MD

Blood (2012) 120 (21): 2926.

https://doi.org/10.1182/blood.V120.21.2926.2926

Published: 2012

Journal Articles

Hypoxia-Inducible Factor-1 in Multiple Myeloma Progression.

Roberto Ria, Antonia Reale, Simona Berardi, Claudia Piccoli, Giulia Di Pietro, Antonio Basile, Nazareno Capitanio, Angelo Vacca

Blood (2009) 114 (22): 1812.

https://doi.org/10.1182/blood.V114.22.1812.1812

Published: 2009

Journal Articles

Identification of Novel Angiogenic Proteins in Multiple Myeloma Patient-Derived Endothelial Cells Using Proteome-Wide Analysis.

Roberto Ria, Simona Berardi, Antonia Reale, Giulia Di Pietro, Antonio Basile, Rosa Terracciano, Rocco Savino, Angelo Vacca

Blood (2009) 114 (22): 2825.

https://doi.org/10.1182/blood.V114.22.2825.2825

Published: 2009

NARROW

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Hypoxia-Inducible Factor-1 in Multiple Myeloma Progression.

Identification of Novel Angiogenic Proteins in Multiple Myeloma Patient-Derived Endothelial Cells Using Proteome-Wide Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only